APA

Kirchheiner J., Kudlicz D., Meisel C., Bauer S., Meineke I., Roots I. & Brockmöller J. (20030828). Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. : Clinical pharmacology and therapeutics.

Chicago

Kirchheiner Julia, Kudlicz Dirk, Meisel Christian, Bauer Steffen, Meineke Ingolf, Roots Ivar and Brockmöller Jürgen. 20030828. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. : Clinical pharmacology and therapeutics.

Harvard

Kirchheiner J., Kudlicz D., Meisel C., Bauer S., Meineke I., Roots I. and Brockmöller J. (20030828). Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. : Clinical pharmacology and therapeutics.

MLA

Kirchheiner Julia, Kudlicz Dirk, Meisel Christian, Bauer Steffen, Meineke Ingolf, Roots Ivar and Brockmöller Jürgen. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. : Clinical pharmacology and therapeutics. 20030828.